drug
as of 2026-07-01RO4917838
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Hoffmann-La Roche
4 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
Trials
4
A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)
NCT01235520Phase 3Completed
A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
NCT01192867Phase 3Completed
A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective Disorder
NCT01116830Phase 1Completed
A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.
NCT00616798Phase 2Completed
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
indication
indication
indication